This study is testing a drug called ML-007C-MA to see if it can help reduce hallucinations and delusions in people with Alzheimer's disease psychosis (ADP). Researchers will compare ML-007C-MA to a placebo (an inactive pill that looks like the study drug). We are looking for about 300 participants, aged 55 to 90, who have been diagnosed with possible or probable Alzheimer's disease and are experiencing hallucinations and delusions. The main goal is to see if ML-007C-MA improves these symptoms over 7 weeks, as measured by a specific rating scale called the Neuropsychiatric Inventory-Clinician: Hallucinations and Delusions (NPI-C H+D) score. The study status is currently unclear.

Study design

This is a Phase 2, randomized, double-blind, placebo-controlled study, meaning participants will be randomly assigned to receive either ML-007C-MA or a placebo, and neither you nor your doctor will know which you are receiving. The study plans to enroll about 300 participants.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

The primary outcome is measured at the end of treatment, which is 7 weeks.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.